Procedure of hybridoma technology
•Download as PPTX, PDF•
1 like•1,102 views
The procedure of hybridoma technology involves extracting lymphocytes from an immunized animal's spleen, mixing them with myeloma cells that do not produce their own antibodies, and culturing the hybrid cells in a selective HAT medium. This allows the hybrid cells that produce the desired antibodies to survive indefinitely for isolation and culture, enabling a continuous production of monoclonal antibodies from the cloned hybridoma cells.
Report
Share
Report
Share
Recommended
Hybridoma & monoclonal antibody
- Monoclonal antibodies are identical antibodies produced by a single clone of B cells or hybridoma. They are produced by fusing B cells from an immunized animal with myeloma cells.
- The hybridoma technique involves immunizing an animal, isolating spleen B cells, fusing them with myeloma cells using polyethylene glycol, and screening clones to identify those that produce the desired antibody.
- Hybridomas are immortal cell lines that can produce large quantities of identical monoclonal antibodies directed against a specific antigen or epitope. This technique allows mass production of antibodies for research, diagnostic, and therapeutic uses.
Hybridoma Technology & its application in fisheries
The document discusses the process of producing monoclonal antibodies through hybridoma technology. It involves fusing antibody-producing B-lymphocytes with myeloma tumor cells to create a hybrid cell that can divide indefinitely and produce antibodies of a single specificity. The process includes immunizing mice, fusing their spleen cells with tumor cells, selecting antibody-producing hybridomas through HAT medium, and harvesting monoclonal antibodies through in vitro or in vivo methods for various medical applications. While this technology has improved disease diagnosis and treatment, it remains inefficient and labor-intensive.
Monoclonal Antibody Production via Hybridoma Technology
Monoclonal antibodies are identical antibodies that bind to a single antigen or epitope. They are produced through hybridoma technology which involves fusing antibody-producing spleen cells with myeloma tumor cells to create immortalized cell lines that secrete the desired antibody. The hybridoma cells are screened using techniques like ELISA or FACS to identify clones that secrete antibodies targeting the antigen of interest. Selected clones are grown in culture medium or injected into mice to produce antibody-rich ascites fluid for harvesting large amounts of monoclonal antibodies.
Hybridoma technology
Hybridoma technology involves fusing B lymphocytes that produce antibodies with myeloma tumor cells to form hybridoma cells. These hybridoma cells can divide indefinitely like tumor cells while also producing monoclonal antibodies of a single specificity, as derived from the B lymphocytes. Georges Kohler and Cesar Milstein developed this technique in 1975 and were awarded the Nobel Prize for it. Their work enabled the large-scale production of monoclonal antibodies with various applications, including disease diagnosis, drug development, and PET imaging using radiolabeled antibodies.
monoclonal antibody production & hybridization and charecterization
monoclonal antibody production hybridization and charecterization
hybridoma screening, priming, methods of antibody charecterization
Development of hybridoma kk
1. A hybridoma is a hybrid cell produced by fusing an antibody-producing cell (usually a B lymphocyte) with a myeloma cell. This allows the cell to produce monoclonal antibodies indefinitely in culture.
2. To produce monoclonal antibodies, B lymphocytes are isolated from an immunized animal and fused with myeloma cells using polyethylene glycol. The resulting hybridomas are selected in HAT medium, which allows only fused cells to survive and proliferate.
3. Once a hybridoma producing the desired antibody is identified, it can be cultured indefinitely to produce large amounts of monoclonal antibodies, which have applications in research, diagnostics and therapeutics.
Hybridoma technology
Hybridoma technology is a technique for producing monoclonal antibodies. It involves fusing antibody-producing B cells with myeloma cells to create a hybrid cell called a hybridoma. Hybridomas are immortal and produce monoclonal antibodies that are identical copies and bind to the same epitope of an antigen. Georges Köhler and César Milstein first developed this technique in 1975, for which they received the Nobel Prize. Their work allowed for the large-scale production of monoclonal antibodies with applications in cancer detection, treatment of autoimmune diseases, and more.
Hybridoma technology and application for monoclonal antibodies
Monoclonal antibodies are identical antibodies produced by a single clone of B cells or hybridoma cells. They are produced through the fusion of myeloma cells with spleen cells from immunized mice. Georges Köhler and Cesar Milstein were the first to produce monoclonal antibodies using this hybridoma technique in 1975, for which they received the Nobel Prize in 1984. Monoclonal antibodies have many important applications in medicine for diagnosis, imaging, and treatment of diseases like cancer, infections, and pregnancy testing.
Recommended
Hybridoma & monoclonal antibody
- Monoclonal antibodies are identical antibodies produced by a single clone of B cells or hybridoma. They are produced by fusing B cells from an immunized animal with myeloma cells.
- The hybridoma technique involves immunizing an animal, isolating spleen B cells, fusing them with myeloma cells using polyethylene glycol, and screening clones to identify those that produce the desired antibody.
- Hybridomas are immortal cell lines that can produce large quantities of identical monoclonal antibodies directed against a specific antigen or epitope. This technique allows mass production of antibodies for research, diagnostic, and therapeutic uses.
Hybridoma Technology & its application in fisheries
The document discusses the process of producing monoclonal antibodies through hybridoma technology. It involves fusing antibody-producing B-lymphocytes with myeloma tumor cells to create a hybrid cell that can divide indefinitely and produce antibodies of a single specificity. The process includes immunizing mice, fusing their spleen cells with tumor cells, selecting antibody-producing hybridomas through HAT medium, and harvesting monoclonal antibodies through in vitro or in vivo methods for various medical applications. While this technology has improved disease diagnosis and treatment, it remains inefficient and labor-intensive.
Monoclonal Antibody Production via Hybridoma Technology
Monoclonal antibodies are identical antibodies that bind to a single antigen or epitope. They are produced through hybridoma technology which involves fusing antibody-producing spleen cells with myeloma tumor cells to create immortalized cell lines that secrete the desired antibody. The hybridoma cells are screened using techniques like ELISA or FACS to identify clones that secrete antibodies targeting the antigen of interest. Selected clones are grown in culture medium or injected into mice to produce antibody-rich ascites fluid for harvesting large amounts of monoclonal antibodies.
Hybridoma technology
Hybridoma technology involves fusing B lymphocytes that produce antibodies with myeloma tumor cells to form hybridoma cells. These hybridoma cells can divide indefinitely like tumor cells while also producing monoclonal antibodies of a single specificity, as derived from the B lymphocytes. Georges Kohler and Cesar Milstein developed this technique in 1975 and were awarded the Nobel Prize for it. Their work enabled the large-scale production of monoclonal antibodies with various applications, including disease diagnosis, drug development, and PET imaging using radiolabeled antibodies.
monoclonal antibody production & hybridization and charecterization
monoclonal antibody production hybridization and charecterization
hybridoma screening, priming, methods of antibody charecterization
Development of hybridoma kk
1. A hybridoma is a hybrid cell produced by fusing an antibody-producing cell (usually a B lymphocyte) with a myeloma cell. This allows the cell to produce monoclonal antibodies indefinitely in culture.
2. To produce monoclonal antibodies, B lymphocytes are isolated from an immunized animal and fused with myeloma cells using polyethylene glycol. The resulting hybridomas are selected in HAT medium, which allows only fused cells to survive and proliferate.
3. Once a hybridoma producing the desired antibody is identified, it can be cultured indefinitely to produce large amounts of monoclonal antibodies, which have applications in research, diagnostics and therapeutics.
Hybridoma technology
Hybridoma technology is a technique for producing monoclonal antibodies. It involves fusing antibody-producing B cells with myeloma cells to create a hybrid cell called a hybridoma. Hybridomas are immortal and produce monoclonal antibodies that are identical copies and bind to the same epitope of an antigen. Georges Köhler and César Milstein first developed this technique in 1975, for which they received the Nobel Prize. Their work allowed for the large-scale production of monoclonal antibodies with applications in cancer detection, treatment of autoimmune diseases, and more.
Hybridoma technology and application for monoclonal antibodies
Monoclonal antibodies are identical antibodies produced by a single clone of B cells or hybridoma cells. They are produced through the fusion of myeloma cells with spleen cells from immunized mice. Georges Köhler and Cesar Milstein were the first to produce monoclonal antibodies using this hybridoma technique in 1975, for which they received the Nobel Prize in 1984. Monoclonal antibodies have many important applications in medicine for diagnosis, imaging, and treatment of diseases like cancer, infections, and pregnancy testing.
Hybridoma technology
The hybridoma technique was developed in 1975 by Georges Kohler and Cesar Milstein. It involves fusing B lymphocytes that produce antibodies against a specific antigen with myeloma cells to form a hybrid cell or hybridoma. This hybridoma has the ability to produce antibodies from the B cell and can divide continuously like the myeloma cell. The hybridomas are screened and isolated to produce monoclonal antibodies of a single specificity. This hybridoma technology provides a way to produce large quantities of monoclonal antibodies.
Monoclonal antibodies & hybridoma technology
Monoclonal antibodies are produced from a single clone of cells and bind to the same epitope. They are produced using hybridoma technology which involves fusing antibody-secreting B cells with myeloma cells to form immortal hybridoma cells that secrete monoclonal antibodies. This technique was developed by Kohler and Milstein in 1975 and they received the Nobel Prize.
hybridoma technology
Hybridoma technology allows the production of monoclonal antibodies through the fusion of B lymphocytes and myeloma cells. This produces a hybrid cell called a hybridoma that can divide indefinitely and secrete antibodies of a single specificity. The document discusses the objectives, definition, history, principle, types of antibodies, production of monoclonal antibodies using hybridoma technology, and its applications in plants for producing therapeutic monoclonal antibodies known as plantibodies. Hybridoma technology has revolutionized monoclonal antibody production and their use in research, diagnostics and therapeutics.
Production of Monoclonal Antibodies and its application : Rituximab
The document describes the process for producing monoclonal antibodies. Mice are immunized with an antigen to elicit an immune response. Spleen cells from mice with high antibody titers are then fused with myeloma cells to generate immortal hybridoma cells. These hybridoma cells are screened and those that secrete the desired antibodies are isolated and mass cultured to produce monoclonal antibodies specific to the target antigen.
MONOCLONAL ANTIBODIES-HYBRIDOMA TECHNOLOGY-APPLICATIONS
Monoclonal antibodies are produced from single clones of B cells and bind to a specific epitope. Georges Köhler and Cesar Milstein developed hybridoma technology in 1975, which involves fusing B cells with myeloma cells to generate immortal hybridoma cell lines that secrete monoclonal antibodies. Hybridomas are selected by growing the cells in HAT medium, which kills unfused cells but allows hybridomas to survive and proliferate indefinitely. Monoclonal antibodies have numerous applications including cancer immunotherapy, diagnostic tests, and treatment of various diseases due to their high specificity and stability.
Monoclonal antibodies
Monoclonal antibodies are antibodies that are identical because they come from identical immune cells that are clones of a unique parent cell. They are produced through hybridoma technology which involves fusing myeloma cells with antibody producing immune cells to produce immortal hybridoma cell lines. Monoclonal antibodies have various applications including diagnostic tests, purification of proteins, cancer therapy, and treatment of autoimmune and inflammatory diseases. Common types of monoclonal antibodies include murine, chimeric, humanized, and fully human antibodies.
Hybridoma Technology
Hybridoma technology is a method for producing large numbers of identical antibodies (also called monoclonal antibodies). This process starts by injecting a mouse (or other mammals) with an antigen that provokes an immune response.
Monoclonal antibodies
- Georges Köhler and Cesar Milstein developed hybridoma technology in 1975 for which they received the Nobel Prize in 1984. Hybridoma technology involves fusing myeloma cells with antibody-producing immune cells to create immortal cell lines that produce monoclonal antibodies.
- Monoclonal antibodies are identical antibodies produced by a single clone and recognize a specific antigen, whereas polyclonal antibodies are derived from different cell lines.
- Hybridoma technology involves immunizing an animal, fusing its immune cells with myeloma cells, selecting and cloning hybridoma cells that produce the desired antibody, and characterizing and storing the monoclonal antibody produced. Monoclonal antibodies have important applications in diagnostics and treatment of diseases like cancer.
Hybridoma technology
Monoclonal antibodies are produced using hybridoma technology which involves fusing myeloma cells with antibody producing spleen cells from immunized mice. The fused cells or hybridomas are selected in HAT medium which allows only the fused cells to survive and grow. The resulting hybridoma cells secrete a single antibody clone that can be mass produced. Key steps include immunizing mice, isolating spleen and myeloma cells, fusing the cells to generate hybridomas, screening and selecting hybridomas that secrete the desired antibody clone, and culturing the selected hybridoma cells to produce monoclonal antibodies. Monoclonal antibodies find various therapeutic applications and can be purified using techniques like affinity chromatography.
Monoclonal antibody
This document discusses monoclonal antibodies (mAbs). It provides a 3 sentence summary:
Monoclonal antibodies are identical antibodies produced by identical immune cells that are clones of a single parent cell. They are produced through the fusion of antibody-producing B cells with myeloma cells to form a hybridoma that replicates indefinitely. This process allows for the mass production of antibodies that are specific to a single antigen or epitope.
Presentation 0 n hybridoma technology
Hybridoma technology is a method for producing monoclonal antibodies by fusing antibody-producing B cells with myeloma cells. This results in a hybrid cell, or hybridoma, that is immortal and produces antibodies of a single specificity. Georges J.F. Kohler and Cesar Milstein developed this technique in 1975 and were later awarded the Nobel Prize. The key steps are immunizing an animal, isolating spleen cells and myeloma cells, fusing them to generate hybridomas, selecting hybridomas using HAT medium, and screening for antibody production. Monoclonal antibodies have applications in research, diagnostics, and therapy.
Hybridoma technology
Hybridoma technology is a method for producing large number of identical antibodies called monoclonal antibodies.
It was discovered by G.kohler and C.milstein in 1975. they were awarded nobel prize for physiology and medicine in 1975.
The hybrid cells are produced by fusing B- lumphocyte with myeloma cells or tumour cells.
The B-lymphocyte have the ability to produce large number of antibodies and tumour cells have indefinite growth.
This is why two cells are used for the production of hybrid cell
Monoclonal antibodies production(1)
The document describes the hybridoma technique for producing monoclonal antibodies. It involves immunizing an animal with an antigen, fusing the animal's antibody-producing B cells with myeloma cells to create hybridomas, and using HAT selection medium to select hybridomas that produce the desired monoclonal antibody. The hybridomas are then screened using ELISA or radioimmunoassay to identify clones that secrete antibodies targeting the specific antigen. Clones that test positive can then be cloned using limiting dilution or soft agar methods to generate stable monoclonal antibody-producing cell lines. Monoclonal antibodies have various applications in areas like diagnostics, imaging, pregnancy testing, and organ transplantation.
Hybridoma technology
Monoclonal antibodies (MAbs) are identical antibodies produced by a single parent cell. MAbs can be created that specifically bind to any substance and then serve to detect or purify that substance. The production of MAbs involves immunizing an animal, fusing the animal's immune B cells with myeloma cells to form a hybridoma, selecting the hybridomas that produce the desired MAb, and propagating the hybridomas to produce large amounts of MAbs. MAbs have many applications including use as diagnostic, therapeutic, and research tools due to their homogeneity, specificity, and ability to be produced in unlimited quantities.
Hybridomatechnology 160204054435
Hybridoma technology involves fusing antibody-producing B cells with myeloma cells to create immortal hybridoma cells that produce monoclonal antibodies. Georges Kohler and Cesar Milstein developed this technique in 1975 and were awarded the 1984 Nobel Prize. Hybridoma cells are cultured using HAT medium to produce monoclonal antibodies that have various diagnostic, therapeutic, and research applications.
Hybridoma cell
Hybridoma cells are created by fusing B lymphocytes from immunized mice with myeloma cells. This fusion produces a hybrid cell that is selected and screened to produce monoclonal antibodies against a specific antigen. The hybridoma technique allows for large-scale, indefinite production of these identical monoclonal antibodies, which have various medical uses such as in treating cancer, rheumatoid arthritis, and cardiovascular diseases. Hybridoma cells can be cultured in vitro or grown in vivo in mice to produce monoclonal antibodies.
Hybridoma technology
Hybridoma technology allows for the production of monoclonal antibodies. It involves fusing antibody-producing B cells with myeloma cells to create a hybridoma cell that is immortal and produces antibodies targeted against a specific antigen. Georges Kohler and Cesar Milstein discovered this technique in 1975 and were later awarded the Nobel Prize for their work. Hybridoma cells are cloned to generate identical daughter cells that secrete monoclonal antibodies, which have various diagnostic, therapeutic, and research applications.
MONOCLONAL ANTIBODIES
This document discusses and compares polyclonal and monoclonal antibodies. Polyclonal antibodies are derived from different B cell lineages and can have batch-to-batch variation, making them less suitable for clinical diagnostic tests. Monoclonal antibodies are derived from a single B cell clone and have greater homogeneity, specificity, and ability to produce unlimited quantities of antibody, enabling their use in diagnostic tests. The document also outlines methods for generating recombinant antibodies and the various therapeutic and diagnostic applications of monoclonal antibodies.
Hybridoma technology
Monoclonal antibodies are produced using hybridoma technology which involves fusing antibody-producing B lymphocytes from mice immunized with antigens with myeloma tumor cells. This fusion produces a hybrid cell called a hybridoma that has the ability to produce antibodies like B lymphocytes and grow indefinitely like tumor cells. Hybridomas allow for the mass production of antibodies that recognize only a single antigen, making them useful research and medical tools.
Antibody engineering by R.S.Priyengha
This document discusses antibody engineering techniques. It begins with an introduction and overview of antibody structure and function. It then describes several methods for engineering antibodies, including the hybridoma method, chimeric method, and humanized method. It provides details on each method and how they work to produce engineered antibodies. Applications of engineered antibodies are also mentioned. Throughout, the document discusses advances in recombinant antibody production and fully human monoclonal antibody techniques.
hybridomatechnology-biotech pharmacy.pptx
Hybridoma technology is a method for generating monoclonal antibodies. It involves fusing antibody-producing B cells from an immunized animal with myeloma tumor cells to create a hybridoma cell. This hybridoma cell is immortal and divides indefinitely while producing antibodies of a single specificity. The key steps are cell fusion, selection in HAT medium which kills unfused cells, screening by ELISA to identify antibody-producing hybridomas, and culturing the hybridomas to produce monoclonal antibodies. Monoclonal antibodies have wide applications in areas like immunoassays, cancer diagnosis and treatment, infectious disease diagnosis, diagnostic imaging, and immunosuppression.
Hybridoma technology for production of monoclonal antibodies.pdf
The document discusses hybridoma technology for producing monoclonal antibodies. It describes the process which involves fusing antibody-producing B cells from immunized mice with myeloma tumor cells, using a chemical or electrical method. The resulting hybridoma cells are selected and cultured, retaining the antibody-producing ability of B cells and indefinite lifespan of tumor cells. The monoclonal antibodies produced can be extracted and purified for therapeutic and research applications.
More Related Content
What's hot
Hybridoma technology
The hybridoma technique was developed in 1975 by Georges Kohler and Cesar Milstein. It involves fusing B lymphocytes that produce antibodies against a specific antigen with myeloma cells to form a hybrid cell or hybridoma. This hybridoma has the ability to produce antibodies from the B cell and can divide continuously like the myeloma cell. The hybridomas are screened and isolated to produce monoclonal antibodies of a single specificity. This hybridoma technology provides a way to produce large quantities of monoclonal antibodies.
Monoclonal antibodies & hybridoma technology
Monoclonal antibodies are produced from a single clone of cells and bind to the same epitope. They are produced using hybridoma technology which involves fusing antibody-secreting B cells with myeloma cells to form immortal hybridoma cells that secrete monoclonal antibodies. This technique was developed by Kohler and Milstein in 1975 and they received the Nobel Prize.
hybridoma technology
Hybridoma technology allows the production of monoclonal antibodies through the fusion of B lymphocytes and myeloma cells. This produces a hybrid cell called a hybridoma that can divide indefinitely and secrete antibodies of a single specificity. The document discusses the objectives, definition, history, principle, types of antibodies, production of monoclonal antibodies using hybridoma technology, and its applications in plants for producing therapeutic monoclonal antibodies known as plantibodies. Hybridoma technology has revolutionized monoclonal antibody production and their use in research, diagnostics and therapeutics.
Production of Monoclonal Antibodies and its application : Rituximab
The document describes the process for producing monoclonal antibodies. Mice are immunized with an antigen to elicit an immune response. Spleen cells from mice with high antibody titers are then fused with myeloma cells to generate immortal hybridoma cells. These hybridoma cells are screened and those that secrete the desired antibodies are isolated and mass cultured to produce monoclonal antibodies specific to the target antigen.
MONOCLONAL ANTIBODIES-HYBRIDOMA TECHNOLOGY-APPLICATIONS
Monoclonal antibodies are produced from single clones of B cells and bind to a specific epitope. Georges Köhler and Cesar Milstein developed hybridoma technology in 1975, which involves fusing B cells with myeloma cells to generate immortal hybridoma cell lines that secrete monoclonal antibodies. Hybridomas are selected by growing the cells in HAT medium, which kills unfused cells but allows hybridomas to survive and proliferate indefinitely. Monoclonal antibodies have numerous applications including cancer immunotherapy, diagnostic tests, and treatment of various diseases due to their high specificity and stability.
Monoclonal antibodies
Monoclonal antibodies are antibodies that are identical because they come from identical immune cells that are clones of a unique parent cell. They are produced through hybridoma technology which involves fusing myeloma cells with antibody producing immune cells to produce immortal hybridoma cell lines. Monoclonal antibodies have various applications including diagnostic tests, purification of proteins, cancer therapy, and treatment of autoimmune and inflammatory diseases. Common types of monoclonal antibodies include murine, chimeric, humanized, and fully human antibodies.
Hybridoma Technology
Hybridoma technology is a method for producing large numbers of identical antibodies (also called monoclonal antibodies). This process starts by injecting a mouse (or other mammals) with an antigen that provokes an immune response.
Monoclonal antibodies
- Georges Köhler and Cesar Milstein developed hybridoma technology in 1975 for which they received the Nobel Prize in 1984. Hybridoma technology involves fusing myeloma cells with antibody-producing immune cells to create immortal cell lines that produce monoclonal antibodies.
- Monoclonal antibodies are identical antibodies produced by a single clone and recognize a specific antigen, whereas polyclonal antibodies are derived from different cell lines.
- Hybridoma technology involves immunizing an animal, fusing its immune cells with myeloma cells, selecting and cloning hybridoma cells that produce the desired antibody, and characterizing and storing the monoclonal antibody produced. Monoclonal antibodies have important applications in diagnostics and treatment of diseases like cancer.
Hybridoma technology
Monoclonal antibodies are produced using hybridoma technology which involves fusing myeloma cells with antibody producing spleen cells from immunized mice. The fused cells or hybridomas are selected in HAT medium which allows only the fused cells to survive and grow. The resulting hybridoma cells secrete a single antibody clone that can be mass produced. Key steps include immunizing mice, isolating spleen and myeloma cells, fusing the cells to generate hybridomas, screening and selecting hybridomas that secrete the desired antibody clone, and culturing the selected hybridoma cells to produce monoclonal antibodies. Monoclonal antibodies find various therapeutic applications and can be purified using techniques like affinity chromatography.
Monoclonal antibody
This document discusses monoclonal antibodies (mAbs). It provides a 3 sentence summary:
Monoclonal antibodies are identical antibodies produced by identical immune cells that are clones of a single parent cell. They are produced through the fusion of antibody-producing B cells with myeloma cells to form a hybridoma that replicates indefinitely. This process allows for the mass production of antibodies that are specific to a single antigen or epitope.
Presentation 0 n hybridoma technology
Hybridoma technology is a method for producing monoclonal antibodies by fusing antibody-producing B cells with myeloma cells. This results in a hybrid cell, or hybridoma, that is immortal and produces antibodies of a single specificity. Georges J.F. Kohler and Cesar Milstein developed this technique in 1975 and were later awarded the Nobel Prize. The key steps are immunizing an animal, isolating spleen cells and myeloma cells, fusing them to generate hybridomas, selecting hybridomas using HAT medium, and screening for antibody production. Monoclonal antibodies have applications in research, diagnostics, and therapy.
Hybridoma technology
Hybridoma technology is a method for producing large number of identical antibodies called monoclonal antibodies.
It was discovered by G.kohler and C.milstein in 1975. they were awarded nobel prize for physiology and medicine in 1975.
The hybrid cells are produced by fusing B- lumphocyte with myeloma cells or tumour cells.
The B-lymphocyte have the ability to produce large number of antibodies and tumour cells have indefinite growth.
This is why two cells are used for the production of hybrid cell
Monoclonal antibodies production(1)
The document describes the hybridoma technique for producing monoclonal antibodies. It involves immunizing an animal with an antigen, fusing the animal's antibody-producing B cells with myeloma cells to create hybridomas, and using HAT selection medium to select hybridomas that produce the desired monoclonal antibody. The hybridomas are then screened using ELISA or radioimmunoassay to identify clones that secrete antibodies targeting the specific antigen. Clones that test positive can then be cloned using limiting dilution or soft agar methods to generate stable monoclonal antibody-producing cell lines. Monoclonal antibodies have various applications in areas like diagnostics, imaging, pregnancy testing, and organ transplantation.
Hybridoma technology
Monoclonal antibodies (MAbs) are identical antibodies produced by a single parent cell. MAbs can be created that specifically bind to any substance and then serve to detect or purify that substance. The production of MAbs involves immunizing an animal, fusing the animal's immune B cells with myeloma cells to form a hybridoma, selecting the hybridomas that produce the desired MAb, and propagating the hybridomas to produce large amounts of MAbs. MAbs have many applications including use as diagnostic, therapeutic, and research tools due to their homogeneity, specificity, and ability to be produced in unlimited quantities.
Hybridomatechnology 160204054435
Hybridoma technology involves fusing antibody-producing B cells with myeloma cells to create immortal hybridoma cells that produce monoclonal antibodies. Georges Kohler and Cesar Milstein developed this technique in 1975 and were awarded the 1984 Nobel Prize. Hybridoma cells are cultured using HAT medium to produce monoclonal antibodies that have various diagnostic, therapeutic, and research applications.
Hybridoma cell
Hybridoma cells are created by fusing B lymphocytes from immunized mice with myeloma cells. This fusion produces a hybrid cell that is selected and screened to produce monoclonal antibodies against a specific antigen. The hybridoma technique allows for large-scale, indefinite production of these identical monoclonal antibodies, which have various medical uses such as in treating cancer, rheumatoid arthritis, and cardiovascular diseases. Hybridoma cells can be cultured in vitro or grown in vivo in mice to produce monoclonal antibodies.
Hybridoma technology
Hybridoma technology allows for the production of monoclonal antibodies. It involves fusing antibody-producing B cells with myeloma cells to create a hybridoma cell that is immortal and produces antibodies targeted against a specific antigen. Georges Kohler and Cesar Milstein discovered this technique in 1975 and were later awarded the Nobel Prize for their work. Hybridoma cells are cloned to generate identical daughter cells that secrete monoclonal antibodies, which have various diagnostic, therapeutic, and research applications.
MONOCLONAL ANTIBODIES
This document discusses and compares polyclonal and monoclonal antibodies. Polyclonal antibodies are derived from different B cell lineages and can have batch-to-batch variation, making them less suitable for clinical diagnostic tests. Monoclonal antibodies are derived from a single B cell clone and have greater homogeneity, specificity, and ability to produce unlimited quantities of antibody, enabling their use in diagnostic tests. The document also outlines methods for generating recombinant antibodies and the various therapeutic and diagnostic applications of monoclonal antibodies.
Hybridoma technology
Monoclonal antibodies are produced using hybridoma technology which involves fusing antibody-producing B lymphocytes from mice immunized with antigens with myeloma tumor cells. This fusion produces a hybrid cell called a hybridoma that has the ability to produce antibodies like B lymphocytes and grow indefinitely like tumor cells. Hybridomas allow for the mass production of antibodies that recognize only a single antigen, making them useful research and medical tools.
Antibody engineering by R.S.Priyengha
This document discusses antibody engineering techniques. It begins with an introduction and overview of antibody structure and function. It then describes several methods for engineering antibodies, including the hybridoma method, chimeric method, and humanized method. It provides details on each method and how they work to produce engineered antibodies. Applications of engineered antibodies are also mentioned. Throughout, the document discusses advances in recombinant antibody production and fully human monoclonal antibody techniques.
What's hot (20)
Production of Monoclonal Antibodies and its application : Rituximab
Production of Monoclonal Antibodies and its application : Rituximab
MONOCLONAL ANTIBODIES-HYBRIDOMA TECHNOLOGY-APPLICATIONS
MONOCLONAL ANTIBODIES-HYBRIDOMA TECHNOLOGY-APPLICATIONS
Similar to Procedure of hybridoma technology
hybridomatechnology-biotech pharmacy.pptx
Hybridoma technology is a method for generating monoclonal antibodies. It involves fusing antibody-producing B cells from an immunized animal with myeloma tumor cells to create a hybridoma cell. This hybridoma cell is immortal and divides indefinitely while producing antibodies of a single specificity. The key steps are cell fusion, selection in HAT medium which kills unfused cells, screening by ELISA to identify antibody-producing hybridomas, and culturing the hybridomas to produce monoclonal antibodies. Monoclonal antibodies have wide applications in areas like immunoassays, cancer diagnosis and treatment, infectious disease diagnosis, diagnostic imaging, and immunosuppression.
Hybridoma technology for production of monoclonal antibodies.pdf
The document discusses hybridoma technology for producing monoclonal antibodies. It describes the process which involves fusing antibody-producing B cells from immunized mice with myeloma tumor cells, using a chemical or electrical method. The resulting hybridoma cells are selected and cultured, retaining the antibody-producing ability of B cells and indefinite lifespan of tumor cells. The monoclonal antibodies produced can be extracted and purified for therapeutic and research applications.
Hybridoma technology
Hybridoma technology is a method for generating monoclonal antibodies by fusing B cells with myeloma cells. Georges Köhler and César Milstein developed this technique in 1975 and were awarded the Nobel Prize for it. The hybridoma cells produced from this fusion have the antibody production ability of B cells and indefinite growth ability of myeloma cells, allowing large-scale monoclonal antibody production. Hybridomas are selected using HAT medium, which eliminates unfused B and myeloma cells. The resulting hybridomas are then screened and cultured to produce monoclonal antibodies, which have wide applications in areas like cancer diagnosis, treatment, and research.
Hybridoma Technology.pdf
Monoclonal antibodies can be produced through hybridoma technology, which was invented in 1975. This involves fusing myeloma cells with antibody-producing lymphocytes from an immunized animal to form immortal hybridoma cells. These hybridoma cells retain the antibody production of lymphocytes and the immortality of myeloma cells. Specifically, the process involves immunizing an animal, fusing its lymphocytes with myeloma cells using polyethylene glycol, selecting hybridoma cells using HAT medium, and isolating antibody-producing clones to produce monoclonal antibodies commercially. Monoclonal antibodies have many diagnostic and therapeutic applications.
Monoclonal antibodies
Students of medical and allied subjects must be exposed to the concept of monoclonal antibodies for the efficient practice of clinical and laboratory medicine.
Monoclonal antibodies and their applications
Various diagnostic tools now a days relied on the Hybriodoma technology and monoclonal antibodies,so this presentation will give some basic information about mAb and Hybridoma technology.
Monoclonal antibodies
Monoclonal antibodies are produced through the hybridoma technology developed by Kohler and Milstein in 1975. This involves fusing B cells from an immunized animal with myeloma cells to produce hybridomas that secrete a single antibody specific to the target antigen. The antibodies can be screened and a clone selected to mass produce monoclonal antibodies that recognize a single epitope. Monoclonal antibodies have various applications including disease diagnosis, immunotherapy, and immunosuppression for organ transplants. While powerful tools, limitations include potential immunogenicity and high production costs.
Synthesis, isolation and importance of monoclonal antibodies
The document discusses monoclonal antibodies (mAbs), including their production using hybridoma technology. It describes how mouse B cells are fused with myeloma cells to generate immortal hybridoma cell lines that secrete a single antibody clone. The monoclonal antibodies produced through this process have various therapeutic applications for treating cancer, transplant rejection, and inflammatory/autoimmune diseases.
Blood grouping Reagents
Antisera are used to determine which antigens are on the red cells.
The test using antisera and the patient's red cells is called the
front cell group.
The polyclonal antisera used in the front group are obtained from
plasma apheresis of donors stimulated with soluble antigens (A
substance from pig mucosa and B substance from horse mucosa).
Alternatively, monoclonal antisera can be prepared from cultured
cell lines.
The development of monoclonal antibodies obtained from cultures
of cells secreting antibodies called hybridomas has made available
a new source of ABO typing reagents.
Antibodies drug delivery system
The document discusses how monoclonal antibodies are produced by fusing B lymphocytes from immunized mice with myeloma cells, screening the resulting hybridomas for the desired antibody specificity using tests like ELISA, and identifying the hybridomas that produce homogenous and specific monoclonal antibodies targeting the antigen of interest.
hYBRIDOMA TECHNOLOGY.pptx
Hybridoma technology allows for the production of monoclonal antibodies through the fusion of antibody-producing B cells with myeloma tumor cells. This results in a hybrid cell that can be cloned to produce many identical daughter cells that secrete the same antibody. Georges Kohler and Cesar Milstein discovered this technique in 1975. Monoclonal antibodies are useful for research, medical diagnostics, and treatments as they are specific to a single epitope.
hybridoma in biotechnology.pptx
Hybridoma technology allows for the production of monoclonal antibodies through the fusion of B cells and myeloma cells. Georges Kohler and Cesar Milstein discovered this technique in 1975. Mouse spleen cells producing antibodies targeting a specific antigen are fused with myeloma cells. The resulting hybridoma cells can be cloned, grown indefinitely in culture, and produce large quantities of identical monoclonal antibodies directed against a single epitope of the target antigen. Monoclonal antibodies find applications in areas such as disease diagnosis, pregnancy testing, and blood typing.
Monoclonal antibodies
Monoclonal antibodies are produced by clones of single B cells that are directed against a single antigen or epitope. Polyclonal antibodies represent a mixture produced by various B cell clones, recognizing multiple epitopes. The hybridoma technology developed by Milstein and Kohler in 1975 involves fusing antibody-producing B cells with myeloma cells to form immortal hybridomas. This allows for the mass production of monoclonal antibodies through selection in HAT medium, where hybridomas survive due to inheriting genes from both parent cells. Monoclonal antibodies have various applications including disease diagnosis, antigen purification, and studying the immune system.
MCAB
Monoclonal antibodies are produced from single clones of B cells and recognize a specific antigen. They have advantages over polyclonal antibodies like homogeneity, specificity, and unlimited production. Monoclonal antibodies are created through cell fusion between B cells and myeloma cells to form immortal hybridoma cells that produce the same antibody. They have various medical uses including cancer therapy, diagnostics, and treatment of autoimmune disorders.
Monoclonal antibody
This document provides information about monoclonal antibodies including their production, types, and applications. It discusses how monoclonal antibodies are produced using the hybridoma technique which fuses antibody producing B cells with myeloma cells. This results in immortal cell lines that produce identical antibodies targeting a single epitope. The document contrasts monoclonal and polyclonal antibodies and describes the evolution of monoclonal antibodies from murine to humanized and human forms to reduce immunogenicity. It also covers monoclonal antibody nomenclature, pharmacokinetics, adverse effects, and therapeutic uses.
Monoclonal antibodies
Monoclonal antibodies (MAbs) are antibodies that are identical and bind to the same epitope. The document discusses the history and development of MAb technology, including the hybridoma technique developed by Kohler and Milstein. It describes how MAbs are produced through cell fusion, screening, and cloning. The document outlines applications of MAbs in diagnostics, such as cancer detection and imaging, and therapeutics, including cancer treatment. MAbs provide advantages over polyclonal antibodies in being highly specific and reproducible.
Monoclonal antibodies explanation .pptx
I am a pharmacist. These slides describe biotechnology topic. I hope students get more benefits about it.
58361240 production-of-monoclonal-antibo (1)
- Hybridoma technology involves fusing antibody-producing B cells with myeloma cancer cells to form immortal hybridoma cell lines capable of producing monoclonal antibodies.
- Cesar Milstein and Georges Kohler invented the technique of producing monoclonal antibodies in 1975, winning the 1984 Nobel Prize for their work.
- The key steps are immunizing an animal like a mouse with an antigen, fusing its spleen B cells with myeloma cells using polyethylene glycol, and culturing the hybridomas in HAT media which selects for cells expressing the desired antibody by killing off other cell types.
MONOCLONAL ANTIBODY PRODUCTION STRATEGY
1. The production of monoclonal antibodies involves immunizing an animal like mice with an antigen, fusing their spleen cells that produce antibodies with myeloma tumor cells, and selecting the resulting hybridoma cells that continuously produce the desired antibodies.
2. The fused hybridoma cells are selected using HAT medium, which allows their growth while killing off unfused spleen and myeloma cells.
3. Individual hybridoma cells are further isolated by limiting dilution to produce monoclonal antibody-secreting clones from which a specific monoclonal antibody can be produced at large scale for commercial purposes.
Conceptual Understanding of Monoclonal Bodies Production via Hybirdoma Techno...
This video is presented by our volunteer Mehwish Khan, she is from Karachi, Pakistan, and she is covering "Monoclonal Bodies Production via Hybirdoma Technology"
for video: https://youtu.be/NilP7HIALvY
#Hybirdoma #antibody #monoclonalantibodies #biology #physiology #health #polyclonalantibody
Similar to Procedure of hybridoma technology (20)
Hybridoma technology for production of monoclonal antibodies.pdf
Hybridoma technology for production of monoclonal antibodies.pdf
Synthesis, isolation and importance of monoclonal antibodies
Synthesis, isolation and importance of monoclonal antibodies
Conceptual Understanding of Monoclonal Bodies Production via Hybirdoma Techno...
Conceptual Understanding of Monoclonal Bodies Production via Hybirdoma Techno...
More from Ash Hassan
Impaired mitochondrial protein synthesis
This document summarizes key aspects of mitochondrial oxidative phosphorylation (OXPHOS). It notes that OXPHOS deficiencies can cause metabolic disorders and affect any organ at any age. The mitochondrial respiratory chain contains over 100 proteins, 13 of which are encoded by mitochondrial DNA while others come from nuclear DNA. Mitochondrial DNA is a 16,569 base pair circular molecule that replicates, transcribes, and translates independently. However, mitochondrial protein synthesis resembles prokaryotes and differs from the universal genetic code and mammalian systems. Defects in mitochondrial or nuclear genes involved in OXPHOS can cause related genetic diseases.
HUMAN DISEASES WITH IMPAIRED MITOCHONDRIAL PROTEIN SYNTHESIS
This document summarizes human diseases related to impaired mitochondrial protein synthesis. It discusses how oxidative phosphorylation provides energy but requires proteins encoded by both nuclear and mitochondrial DNA. Mitochondrial diseases can result from defects in either genome. The review focuses on diseases caused by problems with translating the 13 proteins encoded by mitochondrial DNA. It describes the structure and function of the mitochondrial respiratory chain complexes and DNA. The majority of mitochondrial proteins are nuclear-encoded and involved in processes like respiratory chain assembly and translation of mitochondrial proteins. Defects in these nuclear genes can also cause mitochondrial diseases.
Fuel cells
Fuel cells powered by hydrogen are seen as a key energy solution for the 21st century due to their reduced environmental impact and potential to contribute to energy security. Proton exchange membrane (PEM) fuel cells in particular have been developed for applications in transportation, distributed power generation, and energy storage. However, for widespread adoption challenges remain around transitioning from fossil fuels to a hydrogen economy and developing fuel cell membranes that can operate under more demanding conditions required for automotive and stationary applications like higher temperatures and lower humidity levels. Meeting these challenges will require new membrane materials with sufficient conductivity at low humidity and mechanical reinforcement to withstand operating stresses.
ENDOPLASMIC RETICULUM DYSFUNCTION
This document discusses endoplasmic reticulum (ER) stress and dysfunction. It begins by describing the role of the ER in protein folding and how ER stress occurs when misfolded proteins accumulate. This triggers the unfolded protein response (UPR) to restore homeostasis. Prolonged ER stress can lead to cell death. The document then discusses how ER stress is implicated in various disorders like diabetes and neurodegenerative diseases. It provides details on cerebral hypoxia, describing the types and symptoms, and short and long-term effects of oxygen deprivation in the brain. Treatment focuses on the underlying cause and managing symptoms through therapy.
sustainable nitrogen management
1) The document analyzes long-term groundwater nitrate measurements from Denmark over the past 70 years to assess the sustainability of intensive agricultural nitrogen (N) management in relation to groundwater protection and economic growth.
2) National and European policy initiatives since the 1980s have pushed agricultural N management in Denmark towards more environmentally sustainable practices to protect groundwater from nitrate pollution resulting from excessive N losses.
3) Groundwater nitrate levels correlate strongly with annual agricultural N surpluses. Improved N management has significantly decreased nitrate levels in some areas, although many still exceed groundwater standards. Further measures are needed for more sustainable N use.
Pre processing of groundwater data
This document discusses the pre-processing of groundwater data from monitoring points over eight years to measure nitrate levels. Specific water samples are selected based on nitrate, iron, and oxygen concentrations to minimize uncertainty and enable nitrate sampling years to be converted to groundwater recharge years. This allows for comparison of long-term changes in nitrogen surplus from agriculture to changes in groundwater nitrate levels. Agricultural nitrogen balances of inputs and outputs are also calculated as an indicator of nitrogen lost to the environment. Nitrate pollution levels in groundwater are then evaluated against economic growth rates to examine an environmental curve.
Renewability of Nuclear Energy
This document discusses whether nuclear energy should be considered a renewable or non-renewable energy source. While nuclear energy is based on finite uranium sources, some argue it could be considered renewable if fuel sources like thorium are used. However, others counter that uranium deposits are still limited and nuclear waste storage poses challenges. The debate ultimately comes down to definitions of renewable energy and whether nuclear power can meet requirements like having a sustainably replenished fuel source and avoiding harmful pollution.
Slaughter house policy
The document provides an overview of slaughterhouse policies and procedures in Pakistan. It discusses the general unorganized nature of the meat industry historically and outlines requirements for animals, slaughterers, tools, and facilities. The production process is described including animal intake, slaughter, inspection, and distribution. Suggestions are provided related to cleanliness, waste removal, and siting slaughterhouses away from residential areas.
Agricultural biodiversity
This document summarizes and compares traditional and industrial agricultural systems. Traditional systems are less integrated into markets, rely more on natural capital and agricultural biodiversity, and focus on risk minimization through crop diversity. Industrial systems are more market-integrated, rely more on external inputs and education, focus on maximizing profits through monocultures, and have lower agricultural biodiversity overall. Both systems can contain elements of each other.
enviromental Policy
The Global Change Impact Studies Centre (GCISC) is a Pakistani research institute focused on climate change studies. It conducts research on past and projected climate changes in Pakistan and their impacts. Key areas of research include climate modeling, climate extremes, and greenhouse gas emissions analysis. Over the last decade, GCISC has led several international collaborative projects on topics like climate-smart agriculture, food and water security, and glacier impacts. GCISC also contributes to national climate policy documents and assessments. Its research activities examine issues like monsoon variability, heat waves, water resources, glaciers, and hydrological projections under climate change.
Shampoo industry
This document provides an overview of the shampoo industry, including definitions, history, types of shampoos, formulations, raw materials, manufacturing process, and evaluation methods. It discusses the key ingredients in shampoo such as water, detergents, thickeners, and conditioning agents. The manufacturing process involves compounding large batches according to a formula, quality control testing, and filling and packaging individual bottles on a high-speed production line. Shampoos are evaluated based on their foam stability, cleaning power, conditioning effects, and irritation levels.
Metro cash and carry
The document outlines the key aspects of an environmental management system for Metro Cash & Carry, including establishing a committee to review objectives and programs regarding environmental and operational controls. The system aims to identify and reduce negative environmental, health, and safety impacts across the product lifecycle from design to disposal. It also involves keeping an up-to-date register of legal requirements, defining responsibilities, and committing resources to support the effective implementation and maintenance of the system.
Integrating health and biodiversity
Integrating health and biodiversity aims to promote public health and prevent disease through conservation and sustainable use of biodiversity. It recognizes that biodiversity loss and ecosystem degradation negatively impact human health through increased risks of diseases, pollution, and lack of traditional foods and medicines. Achieving integration requires joint efforts across government ministries and sectors to address the environmental and social drivers of biodiversity loss and implement strategies like ecosystem management, controlling invasive species, and promoting sustainable lifestyles. Monitoring progress through indicators will help facilitate timely, evidence-based decisions and global coordination on integrated health and biodiversity goals.
Evaluation of shampoo
This document outlines various tests used to evaluate properties of shampoo such as foam and foam stability, cleaning ability, effect of water hardness, surface tension, surfactant content, rinsing ability, conditioning effects on softness and luster, lubricity, body and texture, irritation and toxicity, dandruff control, and eye irritancy. It describes several methods for testing these properties, including the Ross-Miles foam column test, lather meter test, canvas disk sinking test, and tests involving human hair, rabbit eyes, and a Brookefield viscometer.
Environmental policy
The document discusses the environmental policy of Centaurus Mall in Islamabad, Pakistan. It implemented a policy to charge single men a Rs. 500 non-refundable entry fee to control loitering in the mall. The policy was formulated through identifying the need, assigning a lead responsibility committee, gathering information, drafting and consulting on the policy, finalizing it, and establishing procedures for implementation, monitoring, and reporting.
Environmental managment
Metro Cash and Carry submitted an environmental management report to outline their policies and procedures. The report discusses Metro's commitment to sustainability across their supply chain and operations. It provides details on Metro's sustainable sourcing policies for products like palm oil and seafood. The report also describes Metro's energy and resource management efforts, such as using renewable energy and optimizing equipment for energy efficiency. It concludes with recommendations, such as conducting product life cycle reviews and establishing an environmental management committee.
Biofilms
- Biofilms are groups of microorganisms that attach to each other and often surfaces, and are found nearly everywhere in nature. They can include bacteria, fungi, and protists. Common examples are dental plaque and pond scum.
- Biofilm formation is a complex, multi-step process involving initial attachment, microcolony formation within an extracellular matrix, maturation, and eventual dispersal or detachment of cells. Dispersal allows biofilms to spread and colonize new surfaces.
- Biofilms grow in many habitats and can cause problems like infections, corrosion, and difficulties with sanitation. They are implicated in about 80% of all infections and can involve both gram-positive and gram-negative bacteria as
Aldehydes
Aldehydes such as formaldehyde and glutaraldehyde have wide antimicrobial properties including being sporicidal and fungicidal. However, glutaraldehyde resistance has emerged in some bacteria and it can cause health issues, leading ortho-phthalaldehyde to replace it. Formaldehyde is used as a disinfectant and biocide, including for vaccines and urinary tract infections. Glutaraldehyde is a non-volatile disinfectant preferred over formaldehyde, used in concentrations of 0.1-1.0% as a biocide and sterilant. Ortho-phthalaldehyde is commonly used to disinfect medical instruments.
Biodiversity and human health
This document discusses the links between biodiversity and human health. It begins by defining biodiversity and health, then explores the various interactions between the two. Biodiversity supports human health through ecosystem services like fresh water provision, food production, regulation of infectious diseases, and provision of medicines. Loss of biodiversity can negatively impact these services and human well-being. The social dimensions are also discussed, as vulnerable populations tend to be most affected by biodiversity loss. Unsustainable practices like water pollution from agriculture threaten both ecosystem and human health. Maintaining biodiversity is important for sustaining these services that support livelihoods and quality of life.
Zeropoint interchange Islamabad Pakistan
The document discusses the Zero Point Interchange Project in Islamabad, Pakistan. The project involved constructing an interchange at the intersection of two major roads, Islamabad Highway and Kashmir Highway. The $300 million project was a mega project undertaken by the Capital Development Authority to improve road networks and create barrier-free avenues and underpasses in the capital. The cloverleaf interchange was completed over 24 months from September 2008 to September 2010.
More from Ash Hassan (20)
HUMAN DISEASES WITH IMPAIRED MITOCHONDRIAL PROTEIN SYNTHESIS
HUMAN DISEASES WITH IMPAIRED MITOCHONDRIAL PROTEIN SYNTHESIS
Recently uploaded
Improving the viability of probiotics by encapsulation methods for developmen...
Improving the viability of probiotics by encapsulation methods for developmen...Open Access Research Paper
The popularity of functional foods among scientists and common people has been increasing day by day. Awareness and modernization make the consumer think better regarding food and nutrition. Now a day’s individual knows very well about the relation between food consumption and disease prevalence. Humans have a diversity of microbes in the gut that together form the gut microflora. Probiotics are the health-promoting live microbial cells improve host health through gut and brain connection and fighting against harmful bacteria. Bifidobacterium and Lactobacillus are the two bacterial genera which are considered to be probiotic. These good bacteria are facing challenges of viability. There are so many factors such as sensitivity to heat, pH, acidity, osmotic effect, mechanical shear, chemical components, freezing and storage time as well which affects the viability of probiotics in the dairy food matrix as well as in the gut. Multiple efforts have been done in the past and ongoing in present for these beneficial microbial population stability until their destination in the gut. One of a useful technique known as microencapsulation makes the probiotic effective in the diversified conditions and maintain these microbe’s community to the optimum level for achieving targeted benefits. Dairy products are found to be an ideal vehicle for probiotic incorporation. It has been seen that the encapsulated microbial cells show higher viability than the free cells in different processing and storage conditions as well as against bile salts in the gut. They make the food functional when incorporated, without affecting the product sensory characteristics.
Enhanced action and stakeholder engagement for sustainable peatland management
Enhanced action and stakeholder engagement for sustainable peatland managementGlobal Landscapes Forum (GLF)
Presented by Jan Peters at GLF Peatlands 2024 - The Global Peatlands Assessment: Mapping, Policy, and Action在线办理(lboro毕业证书)拉夫堡大学毕业证学历证书一模一样
学校原件一模一样【微信：741003700 】《(lboro毕业证书)拉夫堡大学毕业证学历证书》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Evolving Lifecycles with High Resolution Site Characterization (HRSC) and 3-D...
The incorporation of a 3DCSM and completion of HRSC provided a tool for enhanced, data-driven, decisions to support a change in remediation closure strategies. Currently, an approved pilot study has been obtained to shut-down the remediation systems (ISCO, P&T) and conduct a hydraulic study under non-pumping conditions. A separate micro-biological bench scale treatability study was competed that yielded positive results for an emerging innovative technology. As a result, a field pilot study has commenced with results expected in nine-twelve months. With the results of the hydraulic study, field pilot studies and an updated risk assessment leading site monitoring optimization cost lifecycle savings upwards of $15MM towards an alternatively evolved best available technology remediation closure strategy.
Epcon is One of the World's leading Manufacturing Companies.
Epcon is One of the World's leading Manufacturing Companies. With over 4000 installations worldwide, EPCON has been pioneering new techniques since 1977 that have become industry standards now. Founded in 1977, Epcon has grown from a one-man operation to a global leader in developing and manufacturing innovative air pollution control technology and industrial heating equipment.
Improving the Management of Peatlands and the Capacities of Stakeholders in I...
Improving the Management of Peatlands and the Capacities of Stakeholders in I...Global Landscapes Forum (GLF)
Presented by Sonya Dewi at GLF Peatlands 2024 - 360 Degree Approach to Improving Capacity of Multiple Stakeholders to Manage Peatland SustainablyWildlife-AnIntroduction.pdf so that you know more about our environment
All about wildlife, if you are fond of animals and wildlife then do follow us for more content like this
Peatland Management in Indonesia, Science to Policy and Knowledge Education
Peatland Management in Indonesia, Science to Policy and Knowledge EducationGlobal Landscapes Forum (GLF)
Presented by Feri Johana at GLF Peatlands 2024 - 360 Degree Approach to Improving Capacity of Multiple Stakeholders to Manage Peatland SustainablyKinetic studies on malachite green dye adsorption from aqueous solutions by A...
Kinetic studies on malachite green dye adsorption from aqueous solutions by A...Open Access Research Paper
Water polluted by dyestuffs compounds is a global threat to health and the environment; accordingly, we prepared a green novel sorbent chemical and Physical system from an algae, chitosan and chitosan nanoparticle and impregnated with algae with chitosan nanocomposite for the sorption of Malachite green dye from water. The algae with chitosan nanocomposite by a simple method and used as a recyclable and effective adsorbent for the removal of malachite green dye from aqueous solutions. Algae, chitosan, chitosan nanoparticle and algae with chitosan nanocomposite were characterized using different physicochemical methods. The functional groups and chemical compounds found in algae, chitosan, chitosan algae, chitosan nanoparticle, and chitosan nanoparticle with algae were identified using FTIR, SEM, and TGADTA/DTG techniques. The optimal adsorption conditions, different dosages, pH and Temperature the amount of algae with chitosan nanocomposite were determined. At optimized conditions and the batch equilibrium studies more than 99% of the dye was removed. The adsorption process data matched well kinetics showed that the reaction order for dye varied with pseudo-first order and pseudo-second order. Furthermore, the maximum adsorption capacity of the algae with chitosan nanocomposite toward malachite green dye reached as high as 15.5mg/g, respectively. Finally, multiple times reusing of algae with chitosan nanocomposite and removing dye from a real wastewater has made it a promising and attractive option for further practical applications.
Recycling and Disposal on SWM Raymond Einyu pptx
Increasing urbanization, rural–urban migration, rising standards of living, and rapid development associated with population growth have resulted in increased solid waste generation by industrial, domestic and other activities in Nairobi City. It has been noted in other contexts too that increasing population, changing consumption patterns, economic development, changing income, urbanization and industrialization all contribute to the increased generation of waste.
With the increasing urban population in Kenya, which is estimated to be growing at a rate higher than that of the country’s general population, waste generation and management is already a major challenge. The industrialization and urbanization process in the country, dominated by one major city – Nairobi, which has around four times the population of the next largest urban centre (Mombasa) – has witnessed an exponential increase in the generation of solid waste. It is projected that by 2030, about 50 per cent of the Kenyan population will be urban.
Aim:
A healthy, safe, secure and sustainable solid waste management system fit for a world – class city.
Improve and protect the public health of Nairobi residents and visitors.
Ecological health, diversity and productivity and maximize resource recovery through the participatory approach.
Goals:
Build awareness and capacity for source separation as essential components of sustainable waste management.
Build new environmentally sound infrastructure and systems for safe disposal of residual waste and replacing current dumpsites which should be commissioned.
Current solid waste management situation:
The status.
Solid waste generation rate is at 2240 tones / day
collection efficiently is at about 50%.
Actors i.e. city authorities, CBO’s , private firms and self-disposal
Current SWM Situation in Nairobi City:
Solid waste generation – collection – dumping
Good Practices:
• Separation – recycling – marketing.
• Open dumpsite dandora dump site through public education on source separation of waste, of which the situation can be reversed.
• Nairobi is one of the C40 cities in this respect , various actors in the solid waste management space have adopted a variety of technologies to reduce short lived climate pollutants including source separation , recycling , marketing of the recycled products.
• Through the network, it should expect to benefit from expertise of the different actors in the network in terms of applicable technologies and practices in reducing the short-lived climate pollutants.
Good practices:
Despite the dismal collection of solid waste in Nairobi city, there are practices and activities of informal actors (CBOs, CBO-SACCOs and yard shop operators) and other formal industrial actors on solid waste collection, recycling and waste reduction.
Practices and activities of these actor groups are viewed as innovations with the potential to change the way solid waste is handled.
CHALLENGES:
• Resource Allocation.
Climate Change All over the World .pptx
Climate change refers to significant and lasting changes in the average weather patterns over periods ranging from decades to millions of years. It encompasses both global warming driven by human emissions of greenhouse gases and the resulting large-scale shifts in weather patterns. While climate change is a natural phenomenon, human activities, particularly since the Industrial Revolution, have accelerated its pace and intensity
Peatlands of Latin America and the Caribbean
Presented by The Global Peatlands Assessment: Mapping, Policy, and Action at GLF Peatlands 2024 - The Global Peatlands Assessment: Mapping, Policy, and Action
Promoting Multilateral Cooperation for Sustainable Peatland management
Presented by Agus Julianto on GLF Peatlands 2024 - 360 Degree Approach to Improving Capacity of Multiple Stakeholders to Manage Peatland Sustainably
Overview of the Global Peatlands Assessment
Presented by Patrick Scheel at GLF Peatlands 2024 - The Global Peatlands Assessment: Mapping, Policy, and Action
Global Peatlands Map and Hotspot Explanation Atlas
Presented by Alexandra Barthelmes at GLF Peatlands 2024 - The Global Peatlands Assessment: Mapping, Policy, and Action
Optimizing Post Remediation Groundwater Performance with Enhanced Microbiolog...
Results of geophysics and pneumatic injection pilot tests during 2003 – 2007 yielded significant positive results for injection delivery design and contaminant mass treatment, resulting in permanent shut-down of an existing groundwater Pump & Treat system.
Accessible source areas were subsequently removed (2011) by soil excavation and treated with the placement of Emulsified Vegetable Oil EVO and zero-valent iron ZVI to accelerate treatment of impacted groundwater in overburden and weathered fractured bedrock. Post pilot test and post remediation groundwater monitoring has included analyses of CVOCs, organic fatty acids, dissolved gases and QuantArray® -Chlor to quantify key microorganisms (e.g., Dehalococcoides, Dehalobacter, etc.) and functional genes (e.g., vinyl chloride reductase, methane monooxygenase, etc.) to assess potential for reductive dechlorination and aerobic cometabolism of CVOCs.
In 2022, the first commercial application of MetaArray™ was performed at the site. MetaArray™ utilizes statistical analysis, such as principal component analysis and multivariate analysis to provide evidence that reductive dechlorination is active or even that it is slowing. This creates actionable data allowing users to save money by making important site management decisions earlier.
The results of the MetaArray™ analysis’ support vector machine (SVM) identified groundwater monitoring wells with a 80% confidence that were characterized as either Limited for Reductive Decholorination or had a High Reductive Reduction Dechlorination potential. The results of MetaArray™ will be used to further optimize the site’s post remediation monitoring program for monitored natural attenuation.
原版制作(Newcastle毕业证书)纽卡斯尔大学毕业证在读证明一模一样
学校原件一模一样【微信：741003700 】《(Newcastle毕业证书)纽卡斯尔大学毕业证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
ENVIRONMENT~ Renewable Energy Sources and their future prospects.
This presentation is for us to know that how our Environment need Attention for protection of our natural resources which are depleted day by day that's why we need to take time and shift our attention to renewable energy sources instead of non-renewable sources which are better and Eco-friendly for our environment. these renewable energy sources are so helpful for our planet and for every living organism which depends on environment.
Recently uploaded (20)
Improving the viability of probiotics by encapsulation methods for developmen...
Improving the viability of probiotics by encapsulation methods for developmen...
Enhanced action and stakeholder engagement for sustainable peatland management
Enhanced action and stakeholder engagement for sustainable peatland management
world-environment-day-2024-240601103559-14f4c0b4.pptx
world-environment-day-2024-240601103559-14f4c0b4.pptx
Evolving Lifecycles with High Resolution Site Characterization (HRSC) and 3-D...
Evolving Lifecycles with High Resolution Site Characterization (HRSC) and 3-D...
Epcon is One of the World's leading Manufacturing Companies.
Epcon is One of the World's leading Manufacturing Companies.
Improving the Management of Peatlands and the Capacities of Stakeholders in I...
Improving the Management of Peatlands and the Capacities of Stakeholders in I...
Wildlife-AnIntroduction.pdf so that you know more about our environment
Wildlife-AnIntroduction.pdf so that you know more about our environment
Peatland Management in Indonesia, Science to Policy and Knowledge Education
Peatland Management in Indonesia, Science to Policy and Knowledge Education
Kinetic studies on malachite green dye adsorption from aqueous solutions by A...
Kinetic studies on malachite green dye adsorption from aqueous solutions by A...
Promoting Multilateral Cooperation for Sustainable Peatland management
Promoting Multilateral Cooperation for Sustainable Peatland management
Global Peatlands Map and Hotspot Explanation Atlas
Global Peatlands Map and Hotspot Explanation Atlas
Optimizing Post Remediation Groundwater Performance with Enhanced Microbiolog...
Optimizing Post Remediation Groundwater Performance with Enhanced Microbiolog...
ENVIRONMENT~ Renewable Energy Sources and their future prospects.
ENVIRONMENT~ Renewable Energy Sources and their future prospects.
Procedure of hybridoma technology
- 2. Lymphocytes are extracted from spleen of an animal Immunized by antigen Subcutaneously or by peritoneal injection
- 3. Enhanced production of B- lymphocytes Increased chances of required hybridoma cells
- 4. Antibody mixed with myeloma cells Not producing antibodies of their own Should contain genetic markers hypoxanthine phospho-ribosyltransferase
- 5. Myeloma cells + antibody producing lymphocytes Hybrid cells + myeloma cells + B-lymphocytes
- 6. Cultured in a selective media HAT medium alongwith drug aminopterin Myeloma cells and B-lymphocytes will die Resulting in hybrid cells Survival due to HGPRT from myeloma cells Indefinite multiplication due to
- 7. Various techniques ELISA (enzyme-linked immunosorbent assay) Hybrid cells producing the required antibodies are isolated and cultured Ensures that single type of antibodies are produced
- 8. Cultured in suitable culture media Injection of hybrid cells in the peritoneal cavity Antibodies isolated from the peritoneal fluid